Amphastar Pharmaceuticals (AMPH)
(Delayed Data from NSDQ)
$47.57 USD
+1.28 (2.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $47.56 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum B VGM
Price, Consensus and EPS Surprise
AMPH 47.57 +1.28(2.77%)
Will AMPH be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for AMPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AMPH
Implied Volatility Surging for Amphastar Pharmaceuticals (AMPH) Stock Options
Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics
AMPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amphastar Pharmaceuticals (AMPH) Tops Q2 Earnings and Revenue Estimates
HCA Healthcare (HCA) Beats on Q2 Earnings, Ups 2024 EPS View
UnitedHealth Group (UNH) Q2 Earnings Beat on Strong Optum Unit
Other News for AMPH
6 Fundamentally Strong Beaten-Up Stocks
Amphastar Pharmaceuticals Inc (AMPH) Trading Down 3.54% on Oct 2
Amphastar Pharmaceuticals Inc (AMPH) Trading 2.97% Higher on Sep 13
Bullish Two Hundred Day Moving Average Cross - AMPH
Amphastar Pharmaceuticals Offers Interesting Growth And Income Prospects